Compare MNMD & TROO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNMD | TROO |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 151.5M |
| IPO Year | N/A | N/A |
| Metric | MNMD | TROO |
|---|---|---|
| Price | $12.61 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $25.78 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 55.8K |
| Earning Date | 11-06-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $15,084,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 247.24 |
| 52 Week Low | $4.70 | $0.49 |
| 52 Week High | $14.43 | $2.62 |
| Indicator | MNMD | TROO |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 70.41 |
| Support Level | $12.19 | $1.21 |
| Resistance Level | $13.45 | $1.75 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 72.07 | 86.89 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.